scispace - formally typeset
Open AccessJournal ArticleDOI

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management

Reads0
Chats0
TLDR
In this article, the authors focus on how sex and reproductive status, genetics, intestinal microbiota diversity, endocrine and metabolic status, as well as physical activity may interact in determining NAFLD/MAFLD heterogeneity.
Abstract
Precision medicine defines the attempt to identify the most effective approaches for specific subsets of patients based on their genetic background, clinical features, and environmental factors. Nonalcoholic fatty liver disease (NAFLD) encompasses the alcohol-like spectrum of liver disorders (steatosis, steatohepatitis with/without fibrosis, and cirrhosis and hepatocellular carcinoma) in the nonalcoholic patient. Recently, disease renaming to MAFLD [metabolic (dysfunction)-associated fatty liver disease] and positive criteria for diagnosis have been proposed. This review article is specifically devoted to envisaging some clues that may be useful to implementing a precision medicine-oriented approach in research and clinical practice. To this end, we focus on how sex and reproductive status, genetics, intestinal microbiota diversity, endocrine and metabolic status, as well as physical activity may interact in determining NAFLD/MAFLD heterogeneity. All these factors should be considered in the individual patient with the aim of implementing an individualized therapeutic plan. The impact of considering NAFLD heterogeneity on the development of targeted therapies for NAFLD subgroups is also extensively discussed.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.

TL;DR: In this paper, a review summarizes the current understanding of the pathogenic mechanisms of NAFLD and provides an insight into the pharmacological targets and emerging therapeutics with specific interventional mechanisms.
Journal ArticleDOI

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

TL;DR: In this article , a review summarizes the current understanding of the pathogenic mechanisms of NAFLD and provides an insight into the pharmacological targets and emerging therapeutics with specific interventional mechanisms.
Journal ArticleDOI

Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity.

TL;DR: In this paper, a review of existing data on the differential contribution of known factors to the pathogenesis and clinical expression of NAFLD, thus determining the different clinical subphenotypes observed in practice.
Journal ArticleDOI

Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update.

TL;DR: In this review, several of the therapeutic agents that have been studied in phase 2 and 3 randomized trials are summarized and the rationale behind the use of combination therapy and the lessons learned from unsuccessful or negative clinical trials are discussed.
Journal ArticleDOI

Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review

TL;DR: It appears likely that there is a link between several endocrine disorders and NAFLD other than the typically known type 2 diabetes mellitus and metabolic syndrome (MS).
References
More filters
Journal ArticleDOI

Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

TL;DR: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous, and random‐effects models were used to provide point estimates of prevalence, incidence, mortality and incidence rate ratios.
Journal ArticleDOI

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

TL;DR: A simple scoring system accurately separates patients with nonalcoholic fatty liver disease with and without advanced fibrosis, rendering liver biopsy for identification ofAdvanced fibrosis unnecessary in a substantial proportion of patients.
Journal ArticleDOI

NAFLD: A multisystem disease

TL;DR: A narrative review focuses on the rapidly expanding body of clinical evidence that supports the concept of NAFLD as a multisystem disease and the factors linkingNAFLD with other extra-hepatic chronic diseases, such as T2DM, CVD, cardiac diseases and CKD.
Related Papers (5)